Carley Tasker1, Vanessa Pizutelli2, Yungtai Lo3, Bharat Ramratnam4,5, Natalie E Roche6, Theresa L Chang1,2. 1. Department of Microbiology, Biochemistry and Molecular Genetics. 2. Public Health Research Institute. 3. Department of Epidemiology & Population Health, Albert Einstein College of Medicine, New York, New York. 4. Lifespan Clinical Research Center. 5. Department of Medicine, Brown University, Providence, Rhode Island, USA. 6. Department of Obstetrics, Gynecology & Women's Health, Rutgers, the State University of New Jersey, New Jersey Medical School, Newark, New Jersey.
Abstract
OBJECTIVES: Depot medroxyprogesterone acetate (Depo-Provera) is the most commonly used injectable hormone contraceptive in Sub-Saharan Africa where HIV incidence is high. We determined the impact of Depo-Provera on cervical immune cells and mediators in healthy women. METHODS: In this longitudinal study, vaginal, endocervical, and rectal swabs were collected at baseline (visit 1), 1 month (visit 2), and 3 months (visit 3) after Depo-Provera injection. Cervical cells were collected by cytobrush and immune markers on cervical CD4 T cells were analyzed by multicolor flow cytometry at three different visits. The levels of immune mediators in cytobrush supernatants as well as vaginal, cervical, and rectal secretions from swabs were analyzed by multiplex assays and ELISA. RESULTS: Compared with baseline levels, we found a significant increase in the frequency of cervical CCR5CD4 T cells and a significant decrease in the frequency of cervical central memory CD4 T cells. Depo-Provera treatment had little effect on expression of immune mediators in rectal mucosa but significantly suppressed numerous immune mediators at cervicovaginal mucosa. Levels of MCP-1, G-CSF, IL-6, IL-10, GM-CSF, and IP-10 were significantly decreased in both vaginal and cervical secretions after Depo-Provera injection. In cervical samples collected by cytobrush, we found reduced levels of 22 of 25 immune mediators after Depo-Provera injection. Changes in immune mediators differed between vaginal and cervical mucosa, demonstrating compartment-specific responses. CONCLUSION: Depo-Provera altered immune profiles of cervical CD4 T cells and suppressed host immune response at cervicovaginal mucosa, suggesting its likely effect on transmission of sexually transmitted infections including HIV.
OBJECTIVES: Depot medroxyprogesterone acetate (Depo-Provera) is the most commonly used injectable hormone contraceptive in Sub-Saharan Africa where HIV incidence is high. We determined the impact of Depo-Provera on cervical immune cells and mediators in healthy women. METHODS: In this longitudinal study, vaginal, endocervical, and rectal swabs were collected at baseline (visit 1), 1 month (visit 2), and 3 months (visit 3) after Depo-Provera injection. Cervical cells were collected by cytobrush and immune markers on cervical CD4 T cells were analyzed by multicolor flow cytometry at three different visits. The levels of immune mediators in cytobrush supernatants as well as vaginal, cervical, and rectal secretions from swabs were analyzed by multiplex assays and ELISA. RESULTS: Compared with baseline levels, we found a significant increase in the frequency of cervical CCR5CD4 T cells and a significant decrease in the frequency of cervical central memory CD4 T cells. Depo-Provera treatment had little effect on expression of immune mediators in rectal mucosa but significantly suppressed numerous immune mediators at cervicovaginal mucosa. Levels of MCP-1, G-CSF, IL-6, IL-10, GM-CSF, and IP-10 were significantly decreased in both vaginal and cervical secretions after Depo-Provera injection. In cervical samples collected by cytobrush, we found reduced levels of 22 of 25 immune mediators after Depo-Provera injection. Changes in immune mediators differed between vaginal and cervical mucosa, demonstrating compartment-specific responses. CONCLUSION: Depo-Provera altered immune profiles of cervical CD4 T cells and suppressed host immune response at cervicovaginal mucosa, suggesting its likely effect on transmission of sexually transmitted infections including HIV.
Authors: Alison C Roxby; David N Fredricks; Katherine Odem-Davis; Kristjana Ásbjörnsdóttir; Linnet Masese; Tina L Fiedler; Stephen De Rosa; Walter Jaoko; James N Kiarie; Julie Overbaugh; R Scott McClelland Journal: J Acquir Immune Defic Syndr Date: 2016-04-01 Impact factor: 3.731
Authors: Elizabeth H Byrne; Melis N Anahtar; Kathleen E Cohen; Amber Moodley; Nikita Padavattan; Nasreen Ismail; Brittany A Bowman; Gregory S Olson; Amanda Mabhula; Alasdair Leslie; Thumbi Ndung'u; Bruce D Walker; Musie S Ghebremichael; Krista L Dong; Douglas S Kwon Journal: Lancet Infect Dis Date: 2015-12-24 Impact factor: 25.071
Authors: Katherine G Michel; Richard P H Huijbregts; Jonathan L Gleason; Holly E Richter; Zdenek Hel Journal: J Acquir Immune Defic Syndr Date: 2015-04-15 Impact factor: 3.731
Authors: Charlene S Dezzutti; Craig W Hendrix; Jeanne M Marrazzo; Zhenyu Pan; Lei Wang; Nicolette Louissaint; Sabah Kalyoussef; N Merna Torres; Florian Hladik; Urvi Parikh; John Mellors; Sharon L Hillier; Betsy C Herold Journal: PLoS One Date: 2011-08-12 Impact factor: 3.240
Authors: K K Smith-McCune; J F Hilton; U Shanmugasundaram; J W Critchfield; R M Greenblatt; D Seidman; S Averbach; L C Giudice; B L Shacklett Journal: Mucosal Immunol Date: 2017-01-04 Impact factor: 7.313
Authors: Raina N Fichorova; Pai-Lien Chen; Charles S Morrison; Gustavo F Doncel; Kevin Mendonca; Cynthia Kwok; Tsungai Chipato; Robert Salata; Christine Mauck Journal: MBio Date: 2015-09-01 Impact factor: 7.867
Authors: Jeremy V Camp; Robert L Wilson; Morgan Singletary; James L Blanchard; Anna Aldovini; Robert W Kaminski; Edwin V Oaks; Pamela A Kozlowski Journal: Vaccine X Date: 2021-06-24